KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Gross Margin: 2011-2025

Historic Gross Margin for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to 99.04%.

  • Travere Therapeutics' Gross Margin rose 162.00% to 99.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 97.63%, marking a year-over-year increase of 242.00%. This contributed to the annual value of 96.68% for FY2024, which is 456.00% up from last year.
  • Travere Therapeutics' Gross Margin amounted to 99.04% in Q3 2025, which was up 0.37% from 98.67% recorded in Q2 2025.
  • Travere Therapeutics' Gross Margin's 5-year high stood at 108.92% during Q4 2021, with a 5-year trough of 86.58% in Q1 2023.
  • In the last 3 years, Travere Therapeutics' Gross Margin had a median value of 96.36% in 2024 and averaged 95.18%.
  • Per our database at Business Quant, Travere Therapeutics' Gross Margin spiked by 1,298bps in 2021 and then plummeted by 1,188bps in 2022.
  • Over the past 5 years, Travere Therapeutics' Gross Margin (Quarterly) stood at 108.92% in 2021, then crashed by 1,188bps to 97.04% in 2022, then crashed by 717bps to 89.87% in 2023, then spiked by 672bps to 96.59% in 2024, then surged by 162bps to 99.04% in 2025.
  • Its Gross Margin stands at 99.04% for Q3 2025, versus 98.67% for Q2 2025 and 94.28% for Q1 2025.